TGTX Relative Valuation
TGTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TGTX is overvalued; if below, it's undervalued.
Historical Valuation
TG Therapeutics Inc (TGTX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 33.26 is considered Overvalued compared with the five-year average of 20.65. The fair price of TG Therapeutics Inc (TGTX) is between 18.95 to 26.63 according to relative valuation methord. Compared to the current price of 32.24 USD , TG Therapeutics Inc is Overvalued By 21.07%.
Relative Value
Fair Zone
18.95-26.63
Current Price：32.24
21.07%
Overvalued
22.95
PE
1Y
3Y
5Y
Trailing
Forward
18.23
EV/EBITDA
TG Therapeutics Inc. (TGTX) has a current EV/EBITDA of 18.23. The 5-year average EV/EBITDA is -10.69. The thresholds are as follows: Strongly Undervalued below -185.31, Undervalued between -185.31 and -98.00, Fairly Valued between 76.62 and -98.00, Overvalued between 76.62 and 163.92, and Strongly Overvalued above 163.92. The current Forward EV/EBITDA of 18.23 falls within the Historic Trend Line -Fairly Valued range.
18.31
EV/EBIT
TG Therapeutics Inc. (TGTX) has a current EV/EBIT of 18.31. The 5-year average EV/EBIT is 12.90. The thresholds are as follows: Strongly Undervalued below -82.43, Undervalued between -82.43 and -34.77, Fairly Valued between 60.56 and -34.77, Overvalued between 60.56 and 108.23, and Strongly Overvalued above 108.23. The current Forward EV/EBIT of 18.31 falls within the Historic Trend Line -Fairly Valued range.
33.26
PS
TG Therapeutics Inc. (TGTX) has a current PS of 33.26. The 5-year average PS is 100.06. The thresholds are as follows: Strongly Undervalued below -305.63, Undervalued between -305.63 and -102.79, Fairly Valued between 302.90 and -102.79, Overvalued between 302.90 and 505.75, and Strongly Overvalued above 505.75. The current Forward PS of 33.26 falls within the Historic Trend Line -Fairly Valued range.
11.73
P/OCF
TG Therapeutics Inc. (TGTX) has a current P/OCF of 11.73. The 5-year average P/OCF is 26.37. The thresholds are as follows: Strongly Undervalued below -344.42, Undervalued between -344.42 and -159.03, Fairly Valued between 211.76 and -159.03, Overvalued between 211.76 and 397.15, and Strongly Overvalued above 397.15. The current Forward P/OCF of 11.73 falls within the Historic Trend Line -Fairly Valued range.
18.63
P/FCF
TG Therapeutics Inc. (TGTX) has a current P/FCF of 18.63. The 5-year average P/FCF is 28.46. The thresholds are as follows: Strongly Undervalued below -233.94, Undervalued between -233.94 and -102.74, Fairly Valued between 159.66 and -102.74, Overvalued between 159.66 and 290.86, and Strongly Overvalued above 290.86. The current Forward P/FCF of 18.63 falls within the Historic Trend Line -Fairly Valued range.
TG Therapeutics Inc (TGTX) has a current Price-to-Book (P/B) ratio of 17.48. Compared to its 3-year average P/B ratio of 30.68 , the current P/B ratio is approximately -43.03% higher. Relative to its 5-year average P/B ratio of 22.38, the current P/B ratio is about -21.91% higher. TG Therapeutics Inc (TGTX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -3.28%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -8.44% , the current FCF yield is about -100.00% lower.
17.48
P/B
Median3y
30.68
Median5y
22.38
0.00
FCF Yield
Median3y
-3.28
Median5y
-8.44
Competitors Valuation Multiple
The average P/S ratio for TGTX's competitors is 69.58, providing a benchmark for relative valuation. TG Therapeutics Inc Corp (TGTX) exhibits a P/S ratio of 33.26, which is -52.20% above the industry average. Given its robust revenue growth of 92.79%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TGTX decreased by 7.36% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 4.63 to 241.73.
The secondary factor is the Revenue Growth, contributed 92.79%to the performance.
Overall, the performance of TGTX in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is TG Therapeutics Inc (TGTX) currently overvalued or undervalued?
What is TG Therapeutics Inc (TGTX) fair value?
How does TGTX's valuation metrics compare to the industry average?
What is the current P/B ratio for TG Therapeutics Inc (TGTX) as of Nov 09 2025?
What is the current FCF Yield for TG Therapeutics Inc (TGTX) as of Nov 09 2025?
What is the current Forward P/E ratio for TG Therapeutics Inc (TGTX) as of Nov 09 2025?